NCT07583134Not yet recruitingPhase 4
Impact of Propranolol Strategies on Myocardial Injury After Breast Cancer Surgery
A Pragmatic Clinical Trial to Evaluate the Impact of Clinical Propranolol Strategies on Myocardial Injury After Non-cardiac Surgery (MINS) in Patients Undergoing Breast Cancer Surgery With Hypertension or Angina
Source: ClinicalTrials.gov · Last updated 15 May 2026
Brief summary (registry, in English)
This study aims to evaluate the impact of using propranolol, a non-selective beta-blocker, on preventing myocardial injury after non-cardiac surgery (MINS) in breast cancer patients who also have hypertension or angina. Stress from surgery and anesthesia can increase sympathetic activity and inflammation, which may lead to heart stress. This pragmatic clinical trial will compare patients who are prescribed propranolol as part of their routine care with those who are not. Researchers will analyze blood samples and surgical tissues collected during normal treatment to observe changes in heart health and the tumor microenvironment.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 27 Apr 2026
- Start date
- 26 May 2026
- Primary completion date
- 23 May 2028
- Lead sponsor
- Chang-Ik Yoon
- Diseases
- High blood pressure
- NCT number
- NCT07583134
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 100
- From 26 May 2026 to the primary completion date, 23 May 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have received β-blockers within 30 days prior to screening.
Other illness
- Patients with active infectious diseases, autoimmune diseases (including specific rheumatic diseases), coagulation disorders, or cardiovascular diseases other than hypertension or angina pectoris.
- Patients with moderate to severe asthma or chronic obstructive pulmonary disease (COPD).
- Patients with a history of malignancy within the past 5 years.
- Patients with systolic blood pressure \< 100 mmHg or heart rate \< 55 beats per minute.
Lab values
- Patients with clinically significant hepatic, hematologic, or renal dysfunction, defined as any of the following:
- ① ANC \<1,500/mm3
- Platelets \<100,000/mm3
- Hb \<9 g/dL
- AST and ALT \> 2.5 x upper limit of normal (ULN) ⑤ Alkaline phosphatase \> 2.5 x ULN ⑥ Total bilirubin \> 1 x ULN ⑦ Serum creatinine \>1.5 x ULN or estimated creatinine clearance \< 60 mL/min (as calculated using the method standard for the institution)
Other
- Patients with distant metastases.
- Patients who are pregnant or breastfeeding at the time of enrollment.
- Patients for whom data collection is considered difficult at the discretion of the investigator.
- Patients who are unable to understand or complete study questionnaires.
Who the study is looking for
- Female patients aged 20 to 70 years.
- Patients diagnosed with hypertension or angina who require medication.
- Patients diagnosed with unilateral, resectable primary breast cancer (ICD-10: C50), Stage I-III.
- ECOG performance status of 0-1.
- Patients scheduled to receive standard postoperative treatment (including adjuvant radiotherapy
- Patients who voluntarily decide to participate and sign the written informed consent form
Age in the registry: 20 years to 70 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Seoul St. Mary's Hospital, The Catholic University of Korea Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.